Loading clinical trials...
Loading clinical trials...
Chronic dialysis patients with end stage renal disease have an increased mortality rate as compared to the age matched healthy population. It is known that chronic inflammation contributes to the high incidence of cardiovascular events in chronic dialysis patients. Dialyzers made by membranes with increased pore size (high cut-off Dialyzer HCO1100) may be beneficial in the elimination of inflammatory mediators and may improve the inflammatory status. Hypothesis: In this study it will be investigated whether the treatment with HCO1100 will improve the inflammatory status of chronic dialysis patients.
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
No
KfH Bachstzelzenweg 4
Halle, Saxony-Anhalt, Germany
KfH-Bismarkstrasse 95-96
Berlin, Germany
Start Date
April 1, 2012
Primary Completion Date
October 1, 2012
Completion Date
July 1, 2013
Last Updated
March 13, 2025
50
ACTUAL participants
HCO1100
DEVICE
P210H
DEVICE
Lead Sponsor
Vantive Health LLC
Collaborators
NCT00397280
NCT06200207
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04638647